# Evidence-based guidelines for the use of extracorporeal membrane oxygenation in Australia and New Zealand using GRADE methodology series part 1: Venovenous extracorporeal membrane oxygenation (VV ECMO) indications and management

**Authors:** Sally F. Newman, Aidan Burrell, Hergen Buscher, Daniel Thomas Chung, Paul Forrest, John Fraser, Craig French, Carol Hodgson, Ryan Ruiyang Ling, Ed Litton, Graeme MacLaren, Andrew McKee, Zachary Munn, Nhi Nguyen, Julia K. Pilowski, Kollengode Ramanathan, Mark Sackley, Kiran Shekar, Myles Smith, Nikki Stamp, Madeline Wilkinson, Bruce Wilson, Priya Nair

PMC · DOI: 10.1016/j.ccrj.2026.100163 · Critical Care and Resuscitation · 2026-02-26

## TL;DR

This paper presents evidence-based guidelines for using venovenous ECMO in adults in Australia and New Zealand, focusing on indications and management.

## Contribution

The novel contribution is the development of region-specific clinical guidelines for VV ECMO using GRADE methodology and expert consensus.

## Key findings

- The guidelines address four core clinical questions about VV ECMO indications and management.
- Recommendations combine evidence-based analysis with expert consensus.
- The paper identifies gaps in current evidence to guide future research.

## Abstract

We aim to provide evidence-based clinical practice guidelines for the use of VV ECMO in adult patients across Australia and New Zealand. Developed by a multidisciplinary panel of clinicians from both countries, alongside a methodologist and patient representatives, these guidelines were produced in accordance with the National Health and Medical Research Council (NHMRC) 2016 standards for guidelines. The GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach was used to assess the certainty of evidence and inform the development of recommendations. These guidelines are intended to support, not replace, clinical judgement and should be applied in the context of individual patient circumstances, values and preferences. In this part one of a three-part series, the Guideline Development Group (GDG) addressed four core clinical questions regarding the indications for and management of VV ECMO in adults. In addition to evidence-based recommendations, this guideline incorporates expert consensus through a well-established process and highlights important gaps in current evidence to guide future research priorities.

## Full-text entities

- **Diseases:** COVID (MESH:D000086382), multiorgan failure (MESH:D051437), VILI (MESH:D055397), Anxiety (MESH:D001007), lung injury (MESH:D055370), Asthma (MESH:D001249), critically ill (MESH:D016638), barotrauma (MESH:D001469), haemorrhagic stroke (MESH:D002543), death (MESH:D003643), influenza A (MESH:D007251), neurologic injury (MESH:D020196), ARDS (MESH:D012128), MV (MESH:D053717), neuromuscular blockade (MESH:D020879), disability (MESH:D009069), functional impairment (MESH:D003072), hypoxic (MESH:D002534), bleeding (MESH:D006470), Depression (MESH:D003866), organ failure (MESH:D009102), hypercapnic respiratory failure (MESH:D012131), Hypercapnia (MESH:D006935), COPD (MESH:D029424)
- **Chemicals:** Venovenous (-), oxygen (MESH:D010100), H2O (MESH:D014867)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12955552/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12955552/full.md

## References

56 references — full list in the complete paper: https://tomesphere.com/paper/PMC12955552/full.md

---
Source: https://tomesphere.com/paper/PMC12955552